Laboratorios Farmacéuticos ROVI - DORIA on target for US NDA in H219
ROVI has announced its pivotal Phase III PRISMA-3 trial continues on track and it expects to file an NDA with the FDA in the second half of 2019....
64 Views
Laboratorios Farmacéuticos ROVI - DORIA low risk, high reward
Laboratorios Farmacéuticos ROVI’s (ROVI) investment case rests on the growth opportunities in its speciality pharmaceuticals portfolio, in...
47 Views
Laboratorios Farmacéuticos ROVI - Stunning growth in speciality pharmaceuticals
Laboratorios Farmacéuticos ROVI (ROVI) reported Q118 operating revenue of €75.8m (+12% y-o-y), driven by strong growth in the speciality...
45 Views
Laboratorios Farmacéuticos ROVI - Steady as she grows
Laboratorios Farmacéuticos ROVI (ROVI) reported FY17 operating revenue of €275.6m (+ 4%), driven by strong growth in the toll manufacturing...
39 Views
Laboratorios Farmaceuticos ROVI - Biosimilar Enoxaparin Launches
ROVI reported operating revenue of €203m for 9M17 (+ 6%), driven by exceptionally strong growth in the toll manufacturing business (+20%). The...
56 Views